Pulse Biosciences (Nasdaq:PLSE) today announced the enrollment of the first patient in its NANOCLAMP AF study for treating ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

A 27-year-old woman underwent a successful robot-assisted mitral valve repair at Apollo Hospitals Bannerghatta, showcasing the growing popularity of minimally invasive cardiac surgery. This advanced ...

Stereotaxis is pushing the positives of its robotic magnetic navigation systems, MAGiC cardiac catheters and EMAGIN ...

Pulse Biosciences PLSE recently reported encouraging late-breaking data from the first-in-human feasibility study of its ...

PRINCETON, N.J., Sept. 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Pulse Biosciences, Inc. is one of them. Pulse Biosciences, Inc. (NASDAQ:PLSE) is advancing bioelectric medicine ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced ...

Dr. Greg Hundley: Yes, Peder, let's go. Dr. Peder Myhre: ...

The Medtronic Endurant stent graft system got FDA approval to remove a warning against use for ruptured abdominal aortic ...

SAN FRANCISCO -- Noninvasive stereotactic radiotherapy (RT) for refractory ventricular tachycardia (VT) achieved outcomes similar to catheter ablation with substantially fewer serious adverse events ...

Arren Williams never expected that a bout of pneumonia in February 2025 would uncover a heart defect he had lived with, undetected, for decades. What initially seemed like a routine illness revealed ...